Despite an increased use of oral therapies, some men may not be receiving adequate treatment for benign prostatic hyperplasia and may still suffer severe adverse complications as a result, according to researchers.
Benign prostatic hyperplasia (BPH), or non-cancerous enlargement of the prostate, is a common condition that affects millions of men each year, and can lead to serious lower urinary tract symptoms, ranging from frequent or painful urination to urinary retention (which can lead to renal failure if left untreated).
Numerous treatments, including oral therapies and minimally invasive surgical procedures, such as a transurethral resection of the prostate (TURP), are available for men with BPH.
University of California, San Diego researchers examined a 20% data sample from the Nationwide Inpatient Sample between 1998 and 2007 and identified 6,409,576 (5.3%) discharges with primary or secondary diagnoses of BPH.
Age-adjusted prevalence for BPH increased from 4.2% to 7.4% over the 10 year period in this group, irrespective of primary diagnosis; however, discharges for primary BPH decreased from 0.86% to 0.47%.
BPH surgery discharges decreased by 51% and those for primary BPH with acute renal failure increased more than 300%.
Discharges for primary BPH with urinary retention, stones or infection remained static without significant change.
These data suggest that, while the prevalence of BPH is increasing, fewer men are receiving surgical treatment and an increasing number are presenting with acute renal failure.
“Oral therapies for BPH are a common first-line treatment that can be effective in many men,” Dr. McVary said. “However, it is imperative that patients be treated promptly if the drugs aren’t working.
“In many cases, surgical treatment for BPH can help prevent urinary retention, which can ultimately lead to acute renal failure that can be life-threatening.”